GCM
KERX

Gruss Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Gruss Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-288,000
Closed -$1.01M – 95
2015
Q3 		$1.01M Buy
288,000
+50,000
+21% +$335K 0.03% 78
2015
Q2 		$2.38M Hold
238,000
– – 0.08% 59
2015
Q1 		$3.03M Buy
+238,000
New +$3.06M 0.12% 52

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gruss Capital Management's KERX Position: Q4 2015 in Review

Gruss Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2015, closing a stake of 288,000 shares — an estimated $1.01M sold.

Gruss Capital Management first reported a position in KERX in Q1 2015 and held it in 3 quarters. The position peaked at $3.03M in Q1 2015. 128 funds tracked by Wall St. Rank hold KERX as of Q4 2015.

  • Gruss Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Gruss Capital Management sold 288,000 Keryx Biopharmaceuticals Inc shares in Q4 2015, an estimated $1.01M.
  • Gruss Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 3 quarters.
  • Gruss Capital Management's Keryx Biopharmaceuticals Inc position peaked at $3.03M in Q1 2015.
  • 128 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2015.

Based on Gruss Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.